Whether opening dedicated treatment centers, establishing partnerships with radiopharmaceutical companies or recruiting program leaders, U.S. health systems are developing and expanding their theranostics capabilities
Here are 10 health systems expanding theranostics:
- Bethlehem, Pa.-based St. Luke’s University Health Network opened a theranostics center at its Anderson Campus in Easton, Pa. The center has four infusion bays, is co-located with the system’s nuclear medicine department and treats patients with low-grade neuroendocrine tumors, prostate cancer and certain thyroid cancers.
- Indianapolis-based Indiana University Health launched a Theranostics Center of Excellence in August, supported in part by a $20 million philanthropic gift. The system has since become the first in the U.S. to administer Pixclara, a newly FDA-approved brain cancer imaging drug.
- Chicago-based Northwestern Medicine received state approval to build the Northwestern Medicine St. George Cancer Institute in Orland Park, Ill., which will offer theranostics treatment services and house a cyclotron. Construction is expected to begin in early 2027. In February, the system launched a multiyear collaboration with Siemens Healthineers that aims to establish a global center of excellence for theranostics.
- Los Angeles-based UCLA Health tapped Amir Iravani, MD, as director of its theranostics program. Dr. Iravani, who previously served as theranostics clinical director at Seattle-based Fred Hutchinson Cancer Center, was also appointed vice chair of clinical research in the department of nuclear medicine and theranostics.
- Tampa, Fla.-based Moffitt Cancer Center launched a radiopharmaceutical program at Speros, its research facility and medical campus in Land O’ Lakes, Fla. The program covers radiopharmaceutical research, development, clinical translation and manufacturing. The program is led by Ghassan El-Haddad, MD, vice chair of radiopharmaceutical and nuclear oncology, and Josh Carpenter, PhD, president of Speros.
- Norfolk, Va.-based Sentara Health will launch Virginia’s first vertically integrated theranostics program in partnership with Grand Rapids, Mich.-based BAMF Health. The program will include radiopharmaceutical production, molecular imaging and molecular therapy.
- Seattle-based UW Medicine’s radiology department and GE HealthCare launched a research collaboration focused on CT and molecular imaging for cardiology, oncology and theranostics. The theranostics work will center on AI-enabled imaging software, radiopharmaceuticals and imaging techniques to support cancer diagnosis, treatment planning and clinical trial matching.
- Peoria, Ill.-based OSF HealthCare plans to expand the OSF Cancer Institute to include space for its theranostics program, along with medical oncology, surgical oncology and research areas. The plans follow the appointment of Robert McWilliams, MD, as deputy director.
- University of Kansas Health System and University of Kansas Medical Center, both based in Kansas City, Kan., and Kansas City, Mo.-based Children’s Mercy partnered with Grand Rapids, Mich.-based BAMF Health to build an integrated theranostics platform for adult and pediatric patients.
- Salt Lake City-based Huntsman Cancer Institute at the University of Utah became the first U.S. academic medical center to manufacture Posluma, a prostate cancer imaging drug. The drug is produced through the institute’s Center for Quantitative Cancer Imaging and Theranostics.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
